相似文献
1
Is EGFR expression important in non-small cell lung cancer?
Thorax. 2006 Feb;61(2):98-9. doi: 10.1136/thx.2005.047936.
2
High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
Clin Lung Cancer. 2014 Jan;15(1):58-66. doi: 10.1016/j.cllc.2013.08.005. Epub 2013 Nov 7.
3
Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Clin Lung Cancer. 2012 Sep;13(5):375-84. doi: 10.1016/j.cllc.2011.11.006. Epub 2012 Jan 27.
4
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.
Thorax. 2006 Feb;61(2):140-5. doi: 10.1136/thx.2005.042275. Epub 2005 Nov 11.
5
The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Clin Adv Hematol Oncol. 2015 Mar;13(3):147-9.
6
Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.
Biomed Res Int. 2018 Jan 16;2018:7181368. doi: 10.1155/2018/7181368. eCollection 2018.
7
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Oncologist. 2005 Aug;10(7):467-70. doi: 10.1634/theoncologist.10-7-467.
8
[Clinical and prognostic importance of the expression of epidermal growth factor receptors in non-small-cell lung carcinoma].
Biull Eksp Biol Med. 1999 Apr;127(4):446-9.
9
Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.
J Clin Oncol. 2010 Feb 20;28(6):903-5. doi: 10.1200/JCO.2009.26.3996. Epub 2010 Jan 25.
10
[Epidermal growth factor receptors and their ligands in non-small-cell lung carcinoma].
Vestn Ross Akad Med Nauk. 1998(5):51-4.
引用本文的文献
1
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.
Front Oncol. 2023 Jun 22;13:1200646. doi: 10.3389/fonc.2023.1200646. eCollection 2023.
2
Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents.
Transl Lung Cancer Res. 2021 Apr;10(4):2032-2047. doi: 10.21037/tlcr-20-552.
3
Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer.
Asian Pac J Cancer Prev. 2020 Nov 1;21(11):3153-3163. doi: 10.31557/APJCP.2020.21.11.3153.
4
Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products.
Mol Oncol. 2021 Feb;15(2):381-406. doi: 10.1002/1878-0261.12849. Epub 2020 Nov 24.
5
Is Melatonin the Cornucopia of the 21st Century?
Antioxidants (Basel). 2020 Nov 5;9(11):1088. doi: 10.3390/antiox9111088.
6
LiGaO:Cr-based theranostic nanoparticles for imaging-guided X-ray induced photodynamic therapy of deep-seated tumors.
Mater Horiz. 2017 Nov 1;4(6):1092-1101. doi: 10.1039/C7MH00442G. Epub 2017 Aug 9.
7
Prognostic Impact of Melatonin Receptors MT1 and MT2 in Non-Small Cell Lung Cancer (NSCLC).
Cancers (Basel). 2019 Jul 17;11(7):1001. doi: 10.3390/cancers11071001.
8
Melatonin and non-small cell lung cancer: new insights into signaling pathways.
Cancer Cell Int. 2019 May 16;19:131. doi: 10.1186/s12935-019-0853-7. eCollection 2019.
9
Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents.
Cancer Inform. 2017 Dec 15;16:1176935117747259. doi: 10.1177/1176935117747259. eCollection 2017.
10
Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy.
Onco Targets Ther. 2016 Feb 25;9:945-8. doi: 10.2147/OTT.S96227. eCollection 2016.
本文引用的文献
1
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.
Thorax. 2006 Feb;61(2):140-5. doi: 10.1136/thx.2005.042275. Epub 2005 Nov 11.
2
Erlotinib in previously treated non-small-cell lung cancer.
N Engl J Med. 2005 Jul 14;353(2):123-32. doi: 10.1056/NEJMoa050753.
3
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
J Natl Cancer Inst. 2005 May 4;97(9):643-55. doi: 10.1093/jnci/dji112.
4
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
J Natl Cancer Inst. 2005 Mar 2;97(5):339-46. doi: 10.1093/jnci/dji055.
5
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
N Engl J Med. 2005 Feb 24;352(8):786-92. doi: 10.1056/NEJMoa044238.
6
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. doi: 10.1073/pnas.0405220101. Epub 2004 Aug 25.
7
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
8
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
N Engl J Med. 2004 May 20;350(21):2129-39. doi: 10.1056/NEJMoa040938. Epub 2004 Apr 29.
9
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
JAMA. 2003 Oct 22;290(16):2149-58. doi: 10.1001/jama.290.16.2149.
10
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
J Clin Oncol. 2003 Oct 15;21(20):3798-807. doi: 10.1200/JCO.2003.11.069. Epub 2003 Sep 2.
Zotero 插件